
Gain Therapeutics (GANX) Stock Forecast & Price Target
Gain Therapeutics (GANX) Analyst Ratings
Bulls say
Gain Therapeutics is attractive because its lead asset GT-02287 has shown consistent target engagement, favorable safety, and biomarker-driven evidence of mechanism in Phase 1a/1b, including an average 81% reduction in CSF glucosylsphingosine at Day 90 and durable MDS-UPDRS stability through Day 150. The case is strengthened by the program’s broad positioning in Parkinson’s disease with or without a GBA1 mutation, expanding Phase 2 plans across the U.S., Australia, and Europe, and by the fact that the FDA has authorized the IND. With approximately $13.1M in cash and cash equivalents at the midpoint of 2026 and a 2Q26 net loss of $0.11 per share, the company appears funded into next year while it advances a potentially disease-modifying platform and a second pipeline candidate, GT-04686.
Bears say
Gain Therapeutics is facing a weak fundamental case because the one-year mean in the 12 completers ended near baseline only after a six-point swing, while MDS-UPDRS II+III scores fluctuated from a 2.9-point improvement at Day 90 to 3.3 points above baseline at Day 270 and 0.5 points above baseline at Day 360. Such volatility, combined with four of 16 extension entrants excluded from the analysis, only two treatment-naive patients among the original 21, and no reported longitudinal medication or deep-brain-stimulation changes, makes it difficult to argue the data show durable disease stabilization. Although Gain reported no new extension safety signal, the liver-enzyme elevations, ALT/AST/GGT increases, and two hospitalized SAEs judged unlikely related still underscore clinical risk without clear efficacy clarity.
This aggregate rating is based on analysts' research of Gain Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Gain Therapeutics (GANX) Analyst Forecast & Price Prediction
Start investing in Gain Therapeutics (GANX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Gain Therapeutics (GANX) Forecast
Gain Therapeutics (GANX) Analyst Forecast & Price Prediction
Start investing in Gain Therapeutics (GANX)
Order type
Buy in
Order amount
Est. shares
0 shares